An alternative approach to assess exchangeability of a test treatment and the standard treatment with normally distributed response

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 2, 2007, Pages 329-338

  Tsong, Yi ^a,b   Shen, Meiyu ^a  

^a Division of Biometrics I   (United States)

^b Office of Biostatistics   (United States)

Author keywords

Coverage percentage; Equivalence test; Exchangeability

Indexed keywords

ANALYTICAL ERROR; ARTICLE; CLINICAL RESEARCH; DRUG RESEARCH; NORMAL DISTRIBUTION; NULL HYPOTHESIS; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS; STOCHASTIC MODEL; VARIANCE;

CLINICAL TRIALS; CONFIDENCE INTERVALS; CONTROLLED CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUGS, GENERIC; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY;

EID: 33947216684     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400601177301     Document Type: Article

References (7)

1. Chow, S. C., Liu, J. P. (2000). Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed. New York: Marcel Dekker, Inc.
2. Esinhart, J. D., Chinchilli, V. M. (1994). Extension to the use of tolerance interval for the assessment of individual bioequivalence. J. Biopharm. Stat. 4:39-52.
3. Faulkenberry, G. D., Daley, J. C. (1970). Sample size for tolerance limits on a normal distribution. Technometrics 12:813-821.
4. Johnson, N. L., Kotz, S., Balakrishnan, N. (1995). Continuous Univariate Distributions. Vol. 2. 2nd ed. New York: John Wiley & Sons.
5. Liu, J. P., Chow, S. C. (1997). A two one-sided tests procedure for assessing individual bioequivalence. J. Biopharm. Stat. 7:49-61.
6. Tsong, Y., Shen, M., Shah, V. P. (2004). Three-stage sequential statistical dissolution testing rules. J. Biopharm. Stat. 14:757-779.
7. Wald, A., Wolfowitz, J. (1946). Tolerance limits for a normal distribution. Ann. Math. Stat. 19:208-215.